Kornimate/medical-research-clean huggingface dataset:
acute revascularization treatment in ischemic stroke patients with covid-19

Conditions: Ischemic Stroke; Covid19

Summary: case-series and cohort studies have shown the feasibility of reperfusion therapies in patients with ischemic stroke and covid-19, but due to the absence of a contemporary control group of non-covid-19 patients, small sample size or lack of long-term outcome assessment, concerns regarding safety and efficacy of these treatments remain to be clarified. taking into account its limitations, some studies documented higher rates of endovascular treatment complications such as clot fragmentation with distal embolization and vessel re-oclusion, to be more difficult to achieve recanalization after endovascular treatment, and higher rates of any intracerebral hemmorhage. the investigators aim is to assess in a large, multicenter and international cohort, the safety and outcomes of acute reperfusion therapies in patients with ischemic stroke and covid-19, by comparison with a contemporary control group of patients with ischemic stroke and without covid-19 from the same centers.


Eligibility criteria:
1. inclusion criteria: * consecutive ischemic stroke patients receiving acute recanalization treatment (intravenous thrombolysis and/or endovascular treatment) up to 24 hours since last time since well, and according to local treatment criteria * from 1st of march 2020 (for chinese centers from 1st january 2020) 2. exclusion criteria: * patients without a pcr- or antigen test within the first 7 days after treatment * patients with nosocomial sars-cov-2 infection after receiving acute recanalization treatment - pcr- or antigen test becoming positive more than 7 days after treatment * patients with "suspect/ probable case of sars-cov-2 infection" according to the world health organization definition * symptomatic cases of sars-cov-2 infection with symptoms resolution more than 7 days before treatment * asymptomatic cases of sars-cov-2 infection with treatment performed more than 10 days after first positive test for sars-cov-2

Keywords: intravenous thrombolysis endovascular treatment mechanical thrombectomy
a study of mipasetamab uzoptirine (adct-601) in participants with solid tumors

Conditions: Advanced Solid Tumors

Summary: the primary objective of this study is to identify the recommended phase 2 dose (rp2d) and/or the maximum tolerated dose (mtd), and characterize the safety and tolerability of adct-601 monotherapy and in combination with gemcitabine.


Eligibility criteria:
inclusion criteria: 1. male or female participant aged 18 years or older. 2. pathologic diagnosis of solid tumor malignancy that is locally advanced or metastatic at time of screening: part 1: 1. combination therapy arms: selected sarcoma indications from the following 2 separate categories. * soft tissue sarcoma: leiomyosarcoma, liposarcoma, undifferentiated pleomorphic sarcoma (ups; covering malignant fibrous histiocytoma) and synovial sarcoma. * bone sarcoma: ewing's sarcoma (including extraskeletal), osteosarcoma, and chondrosarcoma. 2. monotherapy arms: * sarcoma indications (including those listed for combination therapy arms) regardless of axl gene amplification status. * nsclc regardless of axl gene amplification status. * solid tumors (lymphomas participants are excluded) with known axl gene amplification. part 2: 1. combination therapy arms: sarcoma indications and paad. 2. monotherapy arms: paad, nsclc and solid tumors with axl expression. 3. participants who are refractory to or intolerant to available standard therapy(ies) known to provide clinical benefit for their condition per investigator judgment. 4. participants with measurable disease as determined by response evaluation criteria in solid tumors (recist) v1.1. 5. eastern cooperative oncology group (ecog) performance status 0 - 1. 6. paad only: royal marsden hospital prognostic score 0 - 1. exclusion criteria: 1. history of recent infection requiring intravenous (iv) antibiotics, iv antiviral, or iv antifungal treatment within 4 weeks of cycle 1 day 1 (c1d1). 2. symptomatic central nervous system (cns) metastases or evidence of leptomeningeal disease (brain magnetic resonance imaging \[mri\] or previously documented cerebrospinal fluid \[csf\] cytology). previously treated asymptomatic cns metastases are permitted provided that the last treatment (systemic anticancer therapy and/or local radiotherapy) was completed ≥4 weeks prior to day 1 except usage of low dose of steroids on a taper (i.e., up to 10 mg prednisone or equivalent on day 1 and consecutive days is permissible if being tapered down). participants with discrete dural metastases are eligible. 3. clinically significant third space fluid accumulation (i.e., ascites requiring drainage or any serosal effusion that is either requiring drainage or associated with shortness of breath). 4. active diarrhea common terminology criteria for adverse events (ctcae) grade 2 or a medical condition associated with chronic diarrhea (such as irritable bowel syndrome, inflammatory bowel disease). 5. use of any other experimental medication within 14 days prior to start of study drug (c1d1).

Keywords: advanced solid tumors mipasetamab uzoptirine adct-601 sarcoma gemcitabine axl pancreatic cancer nsclc
a phase ii study to determine the efficacy and safety of sivelestat in subjects with acute lung injury

Conditions: Respiratory Distress Syndrome, Adult; Acute Lung Injury

Summary: the purpose of this study is to determine whether sivelestat will reduce the amount of time a patient must spend on a ventilator and/or increase the chance of survival of patients with acute lung injury.

acute lung injury often develops as a result of severe infection, sepsis, severe injuries, inhalation of foreign substances into the lungs, or pneumonia. the tissues and blood vessels in the lungs become inflamed, and the body does not receive enough oxygen. patients with this condition are placed on a ventilator to assist with breathing. patients entered into this study will be randomly assigned to one of two treatment groups: a sivelestat group or a placebo group. once entered into the study, patients are monitored for up to 6 months.

Eligibility criteria:
inclusion criteria * show evidence of acute lung injury * be on mechanical ventilation exclusion criteria * have undergone certain organ transplants * have severe underlying medical problems * be unlikely to survive * be pregnant or breast-feeding

Keywords: sivelestat acute lung injury
lag3 expression in triple negative breast cancer

Conditions: Triple Negative Breast Cancer; Immune Checkpoint Inhibitor

Summary: this study is the experimental study for relationship between lag-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.


Eligibility criteria:
inclusion criteria: * planned neoadjuvant chemotherapy * triple negative breast cancer exclusion criteria: * her2-positive breast cancer * hormone receptor positive breast cancer
characteristics of sars-cov-2 reinfection

Conditions: COVID-19

Summary: as the covid-19 pandemic continues and the number of individuals with previous infection rises, numbers of sars-cov-2 reinfection are increasing. the second omicron wave in shanghai, china caused by ba.5-sublineages led to a large fraction of reinfections among ba.2 primary infections. to better understand the sars-cov-2 reinfection rate and clinical severity of reinfections, the investigators conducted a multi-centre cohort study. the investigators hope to provide valuable clinical evidences for reinfections and offer guidance for future policy making.

the investigators used data from huashan hospital, renji hospital, and shanghai jing' an central hospital to collect information on sars-cov-2 primary infections with ba.2 during 1 march to 23 may 2022, and followed up for participants' reinfections with ba.5-lineages during 1 december 2022 to 14 january 2023. after matched 1:1 by age and gender with the reinfection cohort, data of primary infections with ba.5-sublineages were also collected. reinfection cases were defined as having positive covid-19 pcr or antigen test, at least 90 days after participants' first positive testing. basic information, vaccination status, time interval between two infections, and clinical manifestations were collected.

Eligibility criteria:
inclusion criteria: * all pcr- or rat-confirmed sars-cov-2 reinfections were included in the study. exclusion criteria: * patients who did not know if they were reinfected were excluded.

Keywords: reinfection risk factor clinical severity
pre-exposure prophylaxis (prep) rapid access

Conditions: Drug Use; Pre-exposure Prophylaxis (PrEP); Opioid Use Disorder

Summary: the goal of phase 1 is to determine the feasibility and acceptability of an intervention ('rapid prep access') providing people who use drugs (pwud) one-time access to hiv self-testing at the victory program. aim 1: to offer hiv self-testing to pwud in the community through a study called 'rapid prep access'. the study will be carried out at the victory program. aim 2: to determine the feasibility and acceptability of 'rapid prep access' at the victory program.

for phase 1 of the study, participants will be recruited for a one-time baseline interview and hiv self-testing. a questionnaire will also be administered to assess their interest in the hiv prevention pill (prep= pre-exposure prophylaxis), but prep will not be offered. study duration for each participant is one day; participants will not be followed over time. after the prescreener and consent forms are completed, the research assistant (ra) will offer the participant an opportunity to administer an hiv self-test. the participant will be provided the test for unboxing and retrieving the user instructions. all testing will be performed and interpreted by participants. the ra can provide assistance with reading the instruction on how to obtain a proper sample. alternatively, the ra will direct them to information in the package insert which includes support offered by the oraquick® support center. after completing the hivst, the ra will complete the baseline questionnaire with each participant while waiting for the participants' hivst results. after the baseline questionnaire is complete, the ra will conduct satisfaction surveys to assess acceptability of the intervention and interest of prep initiation using redcap.

Eligibility criteria:
inclusion criteria: * english speaking * opioid use that was not prescribed by a health professional in the past 6 months exclusion criteria: * pregnant women * persons with previous hiv diagnosis * individuals currently taking prep * individuals who express desire to harm themselves or others

Keywords: people who inject drugs (pwid) rapid prep access substance use mobile health van
cognitive bias modification for interpretation individuals with chronic musculoskeletal pain

Conditions: Chronic Pain; Musculoskeletal Pain Disorder

Summary: cognitive bias modification for interpretation (cbm-i) trains participants to interpret ambiguous information as neutral or benign, rather than interpret it as being related to pain. the goal of this randomised controlled trial was to explore the feasibility and potential clinical benefits of cbm-i in people with chronic pain and also healthy, pain-free individuals.

this study investigated whether cognitive bias modification for interpretation (cbm-i) could reduce negative emotional response to pain and to pain-related images, and whether reductions in interpretation bias (ib) and fear of pain mediated this effect. participants with chronic musculoskeletal pain (n = 41) were randomised to benign cbm-i or no cbm-i, and healthy participants (n = 41) were randomised to benign cbm-i or pain-related cbm-i. after cbm-i, the study assessed pain-related ib and fear of pain, as well as negative emotional response to exercise-induced pain and images of musculoskeletal pain.

Eligibility criteria:
chronic pain group inclusion criteria * experience musculoskeletal pain (pain in muscles, bones, joints, tendons, or ligaments) that has lasted for at least the last 3 months before enrolment in the study * have visited a healthcare professional for their pain * aged 18-70 years * normal or corrected to normal vision * fluency in the english language exclusion criteria * any known reading difficulty healthy group inclusion criteria * aged 18-70 years * normal or corrected to normal vision * fluency in the english language exclusion criteria * experience frequent or continuous pain for the past three months before enrolment in the study * currently experiencing pain * any known reading difficulty

Keywords: cognitive bias modification interpretation bias
a study of empirical antifungal therapy with itraconazole

Conditions: Neutropenia

Summary: the purpose of this study is to investigate the overall success rate of itraconazole intravenous treatment for a period of more than 7 days.

this is a retrospective study ie, a study that looks backward in time, usually using medical records and interviews with patients who are already known to have a disease, in patients with itraconazole intravenous prescription as an empirical (based on practical experience) antifungal agent. this study collects baseline information about underlying disease, sign of fungal infection, neutropenia (a decrease in white blood cells), neutropenic fever duration and the reason for discontinuation. neutropenia is defined as a neutrophil (white blood cell) count of ≤500 cells/mm3 or a count of ≤1000 cells/mm3 with a predicted decrease to ≤500 cells/mm3. fever is defined as a body temperature ≥38.3 celsius degrees at least once a day with no definite external factor or a body temperature of ≥38 celsius degrees continued for at least 1 hour.

Eligibility criteria:
inclusion criteria: * patients with neutropenic fever who receive therapy for inhibiting or preventing development of neoplasms (abnormal growth of tissue) or stem cell transplantation (stem cell is a cell whose daughter cells may differentiate into other cell types) for hematologic malignancies (cancers that affect blood, bone marrow and lymph nodes) * patients who receive itraconazole intravenous (iv) treatment for more than 7 days exclusion criteria: * childbearing women who are pregnant or likely to be pregnant during the study period and men who are neither infertile nor willing to refrain from sexual relations but whose partner does not conduct an effective contraception * fever due to documented fungal infection * hepatic dysfunction * kidney abnormalities * patients who are not eligible for the study participation based on warnings, precautions and contra medications in the package insert of the study drug at the investigator's discretion

Keywords: neutropenia hematologic malignancy itraconazole fungal infection antifungal agent neutropenic fever
ultrasound-guided block for thoracic surgery pain

Conditions: Postoperative Pain; Thoracic Cancer

Summary: the investigators aimed to assess ultrasounde- guided serratus anterior plane block can be effective in acute postoperative pain following thoracic surgery.

analgesic options for thoracotomy are various with each having their own merits and demerits.thoracic epidural is said to be the gold standard for management of thoracotomy pain. however, it is invasive procedure and many side effects. other options include paravertebral block, interpleural block, intrathecal opioids. especially, paravertebral block is thought good alternative to epidural anethesia. most of these invasive neuraxial techniques demand normal coagulation parameters to be present. the serratus anterior plane block(sapb) was done under ultrasound guidance in the mid-axillary line at the level of the fourth rib and the catheter was placed superficial to the serratus plane. the patient expressed relief in pain within 10 minutes of being given the bolus of local anaesthetic.pain following thoracotomy is chiefly due to rib retraction, and damage to the serratus/intercostal muscles and intercostal nerves. a sapb addresses both these aspects. sapb has been mentioned in previous studies for management of rib fractures and breast surgeries. the investigators try to evaluate whether the sapb is easy to perform and provides effective analgesia in patients undergoing thoracotomy with minimal side effects.

Eligibility criteria:
inclusion criteria: •undergoing thoracic surgery (lobectomy or segmentectomy) exclusion criteria: • allergy to any drugs chronic pain disease with medication psychologic disorder anti-depressant drug chronic kidney disease ( cr over 2.0 mg/dl) coagulopathy

Keywords: serratus anterior plane block ultrasound-guided regional anesthesia thoracic surgery postoperative pain
impact of meditation and reiki on assisted reproduction techniques outcomes

Conditions: Infertility

Summary: infertility is estimated to affect 15% of reproductive age couples worldwide and is defined as the inability to conceive after 12 months of unprotected sex for women under 35 or 6 months for women over 35 and is associated with stress, especially due to psychological factors such as anxiety, frustration and depression. in addition, women seeking treatment for pregnancy suffer additional stressors - significant emotional burdens and physical changes that can increase stress and anxiety levels. the possibility of an association between emotional stress and pregnancy outcome in women undergoing assisted reproduction treatment makes important therapies that address the psychological state of these women. meditation and reiki have been used to successfully reduce stress and anxiety in various health contexts. reiki is a complementary health approach in which practitioners lightly place their hands on or just above a person to facilitate their own healing response. reiki has been used as an adjunctive therapy to treat the symptoms common to infertile women seeking treatment, including anxiety, stress, depression, anger, despair and depression. reviews of randomized controlled trials concluded that implementation of the reiki intervention in health centers resulted in mental health benefits, including reduced tension, mental confusion, anxiety and pain as well as improved quality of life. meditation can be defined as a form of mental training aimed at improving an individual's psychological capacities, such as attentional and emotional self-regulation. meditation encompasses a family of practices that include mindfulness meditation, mantra meditation, yoga, tai chi and chi gong. meditation has been used specifically in women undergoing ivf treatment to successfully reduce symptoms related to psychological distress. studies measure the development of self-compassion, mechanisms of emotion regulation, and coping strategies related to infertility and quality of life in infertility. however, only one study showed a relationship between meditation and pregnancy rate. unfortunately, the authors incorporated yoga and psychological approaches into meditation. therefore, we designed this study to evaluate the impact of meditation and reiki on the outcome of assisted reproduction treatment.


Eligibility criteria:
inclusion criteria: * women submitted to embryo transfer * signed informed consent form * fresh or frozen embryo transfer exclusion criteria: * no agreement to participate * no embryo transfer * surrogate embryo transfer

Keywords: in vitro fertilization assisted reproduction pregnancy rate meditation reiki
the "new" place of levetiracetam in the management of status epilepticus in children

Conditions: Epilepsy in Children

Summary: status epilepticus is the leading neurological emergency in children, with mortality 2-7% and significant morbidity (10-20%). it is defined as the occurrence of a crisis lasting more than 5 minutes and requiring the implementation of treatment to stop it and thus limit the immediate and long-term consequences. the research hypothesis is that levetiracetam is non-inferior to phenytoin in terms of cessation and absence of recurrence of status epilepticus, with better clinical tolerance in children from 3 months to 17 years old, with or without epileptic disease, with or without a history of status epilepticus


Eligibility criteria:
inclusion criteria: * minor patient aged 3 months to 17 years * 2nd line treatment with levetiracetam or phenytoin after failure of benzodiazepines * supported in one of the participating centers during the period from november 1, 2019 to may 31, 2023 * subject or parents who have not expressed, after information, their opposition to the reuse of their data for the purposes of this research. exclusion criteria: * patient or parents having expressed their opposition to participating in the study.

Keywords: epilepsy epilepsy in children
randomised controlled trial of structured personal care of type 2 diabetes mellitus

Conditions: Diabetes Mellitus; Quality of Health Care; Health Services Research

Summary: the aims of a concluding 14-year follow-up study are: * to investigate what long-term effect the project model for structured, personalized diabetes care has on 1) the patients' mortality and development of diabetic complications, 2) the patients' use of services from the primary and secondary sector, 3) the patients' self-rated health and motivation, and 4) the doctor-patient relationship.

type 2 diabetes (t2dm) is an increasingly common illness that is linked to considerable excessive mortality. there are many indications that treatment of raised blood pressure and blood glucose as well as dyslipidaemia can postpone the development of diabetic complications. treatment of t2dm is primarily done in general practice, where the results are not satisfactory. the purpose of the project is to create a basis so the existing research-based knowledge can be used to improve the quality of diabetes care in general practice. the answer will be based on the information from 1,428 newly diagnosed diabetic patients aged 40 or over who were followed since 1989 in a randomised trial among more than 600 general practitioners. the intervention, which ended at the beginning of 1996, provided optimum conditions for follow-up, doctor-patient communication and treatment, among other ways by training the doctors, producing clinical guidelines and setting individual treatment goals. in the project, the general practitioner is seen as the coordinator of the whole health system's prophylactic efforts in relation to the individual diabetic patient. the aims of a concluding 14-year follow-up are: * to investigate what long-term effect the project model for structured, personalized diabetes care has on 1) the patients' mortality and development of diabetic complications, 2) the patients' use of services from the primary and secondary sector, 3) the patients' self-rated health and motivation, and 4) the doctor-patient relationship.

Eligibility criteria:
inclusion criteria: * all patients aged 40 or older with newly diagnosed diabetes between 1 march 1989 and 28 february 1991 based on hyperglycaemic symptoms or raised blood glucose values measured in general practice exclusion criteria: * threatening somatic disease, severe mental illness, or unwillingness to participate. for our analysis, we also excluded non-white patients and patients whose diagnosis was not established by a blood glucose measurement at a major laboratory within 500 days after diagnosis.

Keywords: diabetes mellitus quality of health care health services research